Core Viewpoint - The company, Jianhui Information, plans to acquire additional equity in Boke Guoxin (Wuhan) Technology Co., Ltd., increasing its ownership from 32% to 70%, thereby making it a subsidiary and consolidating it into the company's financial statements [1] Group 1: Acquisition Details - Jianhui Information will purchase 16.75%, 13.25%, 4%, and 4% equity stakes from four entities for a total of 37.687 million yuan [1] - Post-transaction, the remaining 30% of Boke Guoxin will be held by Zhou Xiaoping [1] Group 2: Strategic Implications - This acquisition is a key move for the company to implement its intelligent development strategy and enhance industry chain collaboration [1] - The increased stake will allow for better integration of technology advantages in automation hardware, software platforms, and medical AI [1] - The collaboration aims to create a more competitive overall solution for smart hospitals and regional healthcare [1]

Group 1 - The company, Jianhui Information Technology Co., Ltd., plans to acquire 70% of the equity in Boke Guoxin (Wuhan) Technology Co., Ltd. through a series of transactions totaling approximately RMB 10,371.02 million [1][3] - The acquisition involves purchasing shares from four entities: Zhou Xiaoping (16.75%), Zepo Investment (13.25%), Boke Yixin (4.00%), and Boke Guoxin (4.00%) [3][4] - The target company is a member of the China Healthcare Information Interconnection Technology Alliance and has passed 13 system tests in the FHIR Connectathon, marking it as a leading healthcare IT enterprise in Central China [1][3] Group 2 - The acquisition is expected to enhance the company's core business by injecting innovative capabilities in medical AI applications, such as the B-Klinik intelligent agent, and will help expand opportunities in smart hospitals and community healthcare [1][3] - The transaction has been approved by the company's board of directors and does not require shareholder meeting approval as it does not constitute a related party transaction or a major asset restructuring [4][5]

Group 1 - The company plans to acquire equity stakes in Boke Guoxin (Wuhan) Technology Co., Ltd. for a total of 10,371.02 million yuan, which includes 3,768.75 million yuan from Zhou Xiaoping, 2,285.63 million yuan from Ze Pu Investment, 637.50 million yuan from Boke Yixin, and 679.14 million yuan from Boke Guoxin [1] - After the completion of the transaction, the company will hold 70% of the equity in the target company [1] - The target company is a member of the China Medical Health Information Interconnection Technology Alliance and HL7 China, and is the first medical information technology enterprise in Central China to pass 13 system tests of FHIR Connectathon [1] Group 2 - The target company's research and development in medical AI applications, such as the B-Klinik intelligent agent, will inject innovative momentum into the company's core business [1] - This acquisition is expected to help the company explore business opportunities in smart hospitals, county-level medical communities, and digital health management [1]

Group 1 - The company, Jianhui Information, announced that its third board meeting was held on February 5, 2026, combining in-person and communication methods [1] - The meeting reviewed documents including a proposal regarding the postponement of certain fundraising projects [1] Group 2 - The article highlights the significant number of elderly individuals living alone in China, estimated to be in the tens of millions, and discusses the challenges they face in aging comfortably [1] - It mentions that the concept of intended guardianship has been present in China for 14 years but is still not fully implemented, indicating a gap in the system [1]

Core Viewpoint - The company, Jianhui Information, is acquiring additional equity in Boke Guoxin (Wuhan) Technology Co., Ltd., increasing its ownership from 32% to 70%, which will make Boke Guoxin a subsidiary and included in the consolidated financial statements [1] Group 1: Transaction Details - The company plans to acquire 16.75%, 13.25%, 4.00%, and 4.00% equity stakes from Zhou Xiaoping, Ze Pu Investment, Boke Yixin, and Boke Guoxin for a total of RMB 37.6875 million, 22.8563 million, 6.375 million, and 6.7914 million respectively [1] - After the transaction, Zhou Xiaoping will hold the remaining 30% of Boke Guoxin [1] Group 2: Strategic Importance - This transaction is a key measure for the company to implement its intelligent development strategy and deepen industry chain collaboration [1] - Increasing the stake in Boke Guoxin will facilitate the integration of both parties' technological advantages in automation hardware, software platforms, and medical AI [1] Group 3: Market Expansion and Innovation - Boke Guoxin is a member of the China Healthcare Information Interconnection Technology Alliance and has extensive development experience with the HL7 international medical information standards, which will aid the company's overseas market expansion [2] - The acquisition will accelerate the company's business development in emerging markets such as county-level medical communities and data governance for medical institutions [2] - The integration of business and resource sharing is expected to enhance the company's technological innovation capabilities and market responsiveness, laying a solid foundation for future performance growth [2]

Group 1 - Company Jianhui Information plans to acquire 38% equity in Boke Guoxin for RMB 73.71 million, increasing its stake from 32% to 70%, making Boke Guoxin a subsidiary [1] - Company Guangshengtang's innovative drug GST-HG141 for hepatitis B has completed the enrollment of 578 participants in its Phase III clinical trial [2] - Company Hongjing Optoelectronics is establishing a partnership with a target scale of RMB 290 million, contributing RMB 3 million as a limited partner [3] Group 2 - Company Hongchang Technology intends to acquire 21% equity in Liangzhi Joint, which will make it the controlling shareholder with a 51% stake [4] - Company Xiexin Integrated has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory phase [5] - Company Xianheng International plans to reduce its shareholding by up to 3%, amounting to a maximum of 12.28 million shares [6] Group 3 - Company Furuijia plans to reduce its repurchased shares by up to 2%, totaling 18.93 million shares [7] - Company Tianqimo is planning to issue shares and pay cash to acquire assets, leading to a temporary suspension of its stock [8] - Company Shuangqiang Technology's director plans to reduce his holdings by up to 0.32% [9] Group 4 - Company Bairun plans to adjust the conversion price of its bonds due to stock prices falling below 85% of the conversion price [11] - Company Dongnan Network has won an EPC project worth RMB 994 million [12] - Company Anhui Energy has appointed Xu Wengong as the new general manager following the resignation of Fang Shiqing [13] Group 5 - Company Lijun plans to invest up to USD 3 million to establish subsidiaries in Hong Kong and Peru [14] - Company Zhenghe Ecology has signed a strategic cooperation agreement with the government of Beijing's Miyun District [15] - Company First Venture has elected Guo Chuan as the chairman of its board [16] Group 6 - Company Changxin Bochuang's shareholder has terminated an agreement to transfer 14.5 million shares [17] - Company Hengrui Medicine's HR091506 tablet application has been accepted by the National Medical Products Administration [18] - Company Hengrui Medicine's SHR-1894 injection has received approval for clinical trials [20] Group 7 - Company Longshen Rongfa has obtained a medical device production license [21] - Company Western Securities reported that its new borrowings exceeded 20% of its net assets [22] - Company Rongfa Nuclear Power's subsidiary has won a project worth RMB 101 million [23] Group 8 - Company Taiji Industry's subsidiary has a pre-bid for the Huahong FAB9B project with a bid amount of RMB 3.778 billion [24] - Company Suzhou High-tech plans to increase its investment in a subsidiary by RMB 780 million through a debt-to-equity swap [26] - Company Electric Power Investment's vice president has resigned due to work changes [27] Group 9 - Company Hengwei Technology reported a 30.13% increase in net profit for 2025 [28] - Company Fangsheng Pharmaceutical's subsidiary has received a drug production license [29] - Company Pilin Bio's subsidiary has received a notice for clinical trial acceptance for a hemostatic drug [31] Group 10 - Company Zhongxin Fluorine Material has received approval for a stock issuance to specific investors [32] - Company Shanhe Intelligent expects a total transaction amount with related parties to be RMB 1.197 billion in 2026 [33] - Company Warner Pharmaceutical's partner has completed Phase I clinical trials for a new drug [34]

Core Viewpoint - The company Jianhui Information (605186) plans to acquire a total of 70% equity in Boke Guoxin (Wuhan) Technology Co., Ltd. through multiple transactions totaling approximately 10.4 million yuan, which will enhance its capabilities in the healthcare information technology sector [1] Group 1: Acquisition Details - Jianhui Information intends to purchase 16.75% equity from Zhou Xiaoping for 37.6875 million yuan, 13.25% from Ze Pu Investment for 22.8563 million yuan, 4.00% from Boke Yixin for 6.375 million yuan, and another 4.00% from Boke Guoxin for 6.7914 million yuan [1] - Upon completion of these transactions, Jianhui Information will hold 70% of the equity in the target company [1] Group 2: Target Company Profile - Boke Guoxin is a member of the China Healthcare Information Interconnection Technology Alliance and HL7 China [1] - The target company is the first healthcare information enterprise in Central China to pass 13 system tests in the FHIR Connectathon [1] Group 3: Strategic Implications - The acquisition is expected to inject innovative intelligence into Jianhui Information's core business, particularly in the development of medical AI applications such as the B-Klinik intelligent agent [1] - This move will help the company explore business opportunities in smart hospitals, county-level medical communities, and digital health management [1]

Core Viewpoint - The company plans to acquire additional equity in Boke Guoxin (Wuhan) Technology Co., Ltd., increasing its ownership from 32% to 70%, making it a subsidiary and consolidating its financials [1][2] Group 1: Acquisition Details - The company will spend a total of 3,768.75 million, 2,285.63 million, 637.50 million, and 679.14 million to acquire 16.75%, 13.25%, 4.00%, and 4.00% equity from various stakeholders [1] - Post-transaction, the remaining 30% equity will be held by Zhou Xiaoping, establishing the company as the controlling shareholder [1] Group 2: Strategic Implications - This acquisition is a key move to implement the company's intelligent development strategy and deepen industry chain collaboration [1] - The increased stake will facilitate the integration of both parties' technological advantages in automation hardware, software platforms, and medical AI [1] - The collaboration aims to enhance the company's core products, such as automated pharmacies and central intravenous admixture services, with AI applications [1] Group 3: Market Expansion - The transaction will accelerate the company's business expansion in emerging markets like county-level medical communities and healthcare data governance [2] - It aims to create a comprehensive smart healthcare service that combines hardware and software with AI [2] - The integration of resources is expected to improve the company's technological innovation capabilities and market responsiveness, laying a solid foundation for future performance growth [2]

Core Viewpoint - The company, Jianhui Information, plans to acquire additional equity in Boke Guoxin (Wuhan) Technology Co., Ltd., increasing its ownership from 32% to 70%, thereby making it a subsidiary and consolidating its financials [1][2] Group 1: Acquisition Details - The company intends to purchase 16.75%, 13.25%, 4.00%, and 4.00% equity stakes from Zhou Xiaoping, Ze Pu Investment, Boke Yixin, and Boke Guoxin for a total of RMB 37.6875 million, 22.8563 million, 6.375 million, and 6.7914 million respectively [1] - Post-transaction, Zhou Xiaoping will retain the remaining 30% equity in the target company [1] Group 2: Strategic Importance - This acquisition is a key move for the company to implement its intelligent development strategy and deepen industry chain collaboration [1] - By increasing its stake, the company aims to integrate its automation hardware, software platforms, and medical AI capabilities with those of the target company [1] Group 3: Market Expansion and Innovation - The target company is a member of the China Healthcare Information Interconnection Technology Alliance and has extensive experience with the HL7 international medical information standards, which will facilitate the company's expansion into overseas markets [2] - The transaction is expected to accelerate the company's business development in emerging markets such as county-level medical communities and data governance for medical institutions [2] - Through business integration and resource sharing, the company aims to enhance its technological innovation capabilities and market responsiveness, laying a solid foundation for future performance growth [2]

国信证券股份有限公司 关于上海健麾信息技术股份有限公司 部分募投项目延期的核查意见 国信证券股份有限公司（以下简称"国信证券"或"保荐机构"）作为上海 健麾信息技术股份有限公司（以下简称"健麾信息"或"公司"）首次公开发行 股票并在主板上市（以下简称"本次发行"）的保荐机构，根据《证券发行上市 保荐业务管理办法》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》《上市公司募集资金监管规则》《上海证券交易所股票上市规则》和《上海 证券交易所上市公司自律监管指引第 11 号——持续督导》等有关规定，就健麾 信息部分募集资金投资项目延期事项进行了审慎核查，核查情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）出具的《关于核 准上海健麾信息技术股份有限公司首次公开发行股票的批复》（证监许可 [2020]3211 号），公司于 2020 年 12 月首次公开发行人民币普通股（A 股） 34,000,000 股。公司每股发行价格为人民币 14.20 元，本次募集资金总额为人民 币 482,800,000.00 元，扣除各项发行费用（不含增值税）人民币 47,588,127. ...